PLAGL2‐EGFR‐HIF‐1/2α Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity
Authors:
- 25 April 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 73 (2) , 674-691
Abstract
Background and Aims: Hepatocellular carcinoma (HCC) is the third leading cause of cancer‐related deaths worldwide, hence a major public health threat. Pleomorphic adenoma gene like‐2 (PLAGL2) has been reported to play a role in tumorigenesis. However, its precise function in HCC remains poorly understood. Approach and Results: In this study, we demonstrated that PLAGL2 was up‐regulated in HCC compared with that of adjacent nontumorous tissues and also correlated with overall survival times. We further showed that PLAGL2 promoted HCC cell proliferation, migration, and invasion both in vitro and in vivo. PLAGL2 expression was positively correlated with epidermal growth factor receptor (EGFR) expression. Mechanistically, this study demonstrated that PLAGL2 functions as a transcriptional regulator of EGFR and promotes HCC cell proliferation, migration, and invasion through the EGFR‐AKT pathway. Moreover, hypoxia was found to significantly induce high expression of PLAGL2, which promoted hypoxia inducible factor 1/2 alpha subunit (HIF1/2A) expression through EGFR. Therefore, this study demonstrated that a PLAGL2‐EGFR‐HIF1/2A signaling loop promotes HCC progression. More importantly, PLAGL2 expression reduced hepatoma cells’ response to the anti‐EGFR drug erlotinib. PLAGL2 knockdown enhanced the response to erlotinib. Conclusions: This study reveals the pivotal role of PLAGL2 in HCC cell proliferation, metastasis, and erlotinib insensitivity. This suggests that PLAGL2 can be a potential therapeutic target of HCC.Keywords
Funding Information
- National Natural Science Foundation of China (81673468)
- National Natural Science Foundation of China (81703561)
This publication has 39 references indexed in Scilit:
- BAY 87‐2243, a highly potent and selective inhibitor of hypoxia‐induced gene activation has antitumor activities by inhibition of mitochondrial complex ICancer Medicine, 2013
- Targeted therapies in medical oncology: successes, failures and next stepsTherapeutic Advances in Medical Oncology, 2013
- Pleiomorphic adenoma gene-like 2 expression is associated with the development of lung adenocarcinoma and emphysemaLung Cancer, 2011
- PLAG1 expression in cutaneous mixed tumors: an immunohistochemical and molecular genetic studyVirchows Archiv, 2011
- The transcription factor PlagL2 activates Mpl transcription and signaling in hematopoietic progenitor and leukemia cellsLeukemia, 2011
- PLAGL2 Regulates Wnt Signaling to Impede Differentiation in Neural Stem Cells and GliomasCancer Cell, 2010
- Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgeryBMC Cancer, 2009
- EMT, the cytoskeleton, and cancer cell invasionCancer and Metastasis Reviews, 2009
- PLAGL2 controls the stability of Pirh2, an E3 ubiquitin ligase for p53Biochemical and Biophysical Research Communications, 2007
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences, 2005